TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24667908

Group type: EXPERIMENTAL
Intervention: Dietary patterns from the DASH study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear mixed model analysis
Number of subjects: 0
Study: 22990034

Group type: EXPERIMENTAL
Intervention: Fasting fMRI scan
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Post-breakfast fMRI scan
Number of subjects: 23
Study: 20672451

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine + zidovudine + lamivudine
Number of subjects: 198

Group type: COMPARATOR
Intervention: Single-dose nevirapine
Number of subjects: 198
Study: 17006363

Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 290

Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 290
Study: 16264111

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves (6000 impulses at 28 kV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Core decompression and nonvascularized fibular grafting
Number of subjects: 48
Study: 12028899

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 4.5 MU/daily for 24 weeks, followed by 4.5 MU/48 hours for a further 24 weeks (if ALT was normal)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 10202389

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 18

Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LDL oxidizability
Number of subjects: 18
Study: 7849295

Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 376
Study: 2351039

Group type: EXPERIMENTAL
Intervention: Fructosamine measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: HbA1 measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall correlation between HbA1 and glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between fructosamine and HbA1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between fructosamine and glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal fructosamine results
Number of subjects: 0
Study: 6966882

Group type: EXPERIMENTAL
Intervention: terodiline 12.5 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30362650

Group type: EXPERIMENTAL
Intervention: CAD/CAM-processed implant crowns
Number of subjects: 20
Study: 27900662

Group type: EXPERIMENTAL
Intervention: Hyalobarrier®
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Hyalobarrier® (control)
Number of subjects: 30
Study: 24531123

Group type: EXPERIMENTAL
Intervention: 50 g dark chocolate
Number of subjects: 21

Group type: COMPARATOR
Intervention: 50 g white chocolate (control)
Number of subjects: 21

Group type: COMPARATOR
Intervention: dark chocolate and white chocolate
Number of subjects: 21
Study: 24603643

Group type: EXPERIMENTAL
Intervention: NEPA (300 mg netupitant + 0.50 mg palonosetron)
Number of subjects: 1455
Study: 22871128

Group type: EXPERIMENTAL
Intervention: Sodium citrate supplementation (600 mg·kg(‐1); CIT group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLC group)
Number of subjects: 16
Study: 19953772

Group type: EXPERIMENTAL
Intervention: SoloBond M two‐step etch‐and‐rinse adhesive
Number of subjects: 16

Group type: COMPARATOR
Intervention: FuturaBond NR one‐step self‐etch adhesive
Number of subjects: 16
Study: 18292704

Group type: EXPERIMENTAL
Intervention: Laboratory research and treatment trials for marijuana dependence; specific interventions not detailed.
Number of subjects: 0
Study: 16801747

Group type: EXPERIMENTAL
Intervention: Local guidelines, de-escalation, rotation and association therapies
Number of subjects: 0
Study: 12546525

Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2 (group A)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 5-FU 500 mg/m2 (group B)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 5-FU 600 mg/m2 (group C)
Number of subjects: 312
Study: 10643517

Group type: EXPERIMENTAL
Intervention: Potassium-para-aminobenzoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen or interferon therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small incision graft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporal shock wave therapy
Number of subjects: 0
Study: 7674464

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 20 micrograms
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 91
Study: 2291867

Group type: EXPERIMENTAL
Intervention: Captopril (12.5, 25, and 50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 14
Study: 6114712

Group type: EXPERIMENTAL
Intervention: Combined H1 (hydroxyzine hydrochloride) and H2 (cimetidine) antihistamines
Number of subjects: 18

Group type: COMPARATOR
Intervention: H1 antihistamines alone
Number of subjects: 18
Study: 31199705

Group type: EXPERIMENTAL
Intervention: Huoxin formula (13.5 g granules dissolved in 150 mL warm water, twice a day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (only cardiovascular drugs)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Huoxin formula
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 28575224

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/d from 14 weeks of gestation until delivery
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study: 28029540

Group type: EXPERIMENTAL
Intervention: Booster dose of combined Haemophilus influenzae type b and MenC‐tetanus toxoid vaccine (Hib‐MenC‐TT)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: One MenC‐TT dose
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Two MenC‐CRM vaccine doses
Number of subjects: 269

Group type: COMPARATOR
Intervention: Infant MenCC naïve group
Number of subjects: 269
Study: 24929023

Group type: EXPERIMENTAL
Intervention: H2-saline infusion (1 ppm H2-dissolved saline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo-saline infusion
Number of subjects: 24
Study: 22344504

Group type: EXPERIMENTAL
Intervention: Enhanced eGFR laboratory prompt
Number of subjects: 5444

Group type: COMPARATOR
Intervention: Standard eGFR laboratory prompt
Number of subjects: 5444

Group type: EXPERIMENTAL
Intervention: Enhanced eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Number of subjects: 5444

Group type: COMPARATOR
Intervention: Standard eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Number of subjects: 5444

Group type: EXPERIMENTAL
Intervention: Overall CKD management (composite clinical outcome)
Number of subjects: 5444
Study: 19546122

Group type: EXPERIMENTAL
Intervention: Silicone bulking agent injection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (20 continent healthy volunteers)
Number of subjects: 35
Study: 17587724

Group type: EXPERIMENTAL
Intervention: Furosemide (short-acting loop diuretic)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Azosemide (long-acting diuretic)
Number of subjects: 300
Study: 14985994

Group type: EXPERIMENTAL
Intervention: Lower trunk accelerations measured by a tri-axial accelerometer during overground walking
Number of subjects: 41
Study: 12231488

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 148
Study: 11305519

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5-mg tablet) plus glucose (10% infusion at 62.5 ml/h for 12 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (glucose alone)
Number of subjects: 0
Study: 9356038

Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined infusion of insulin and norepinephrine (NE)
Number of subjects: 10
Study: 7706591

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cranberry juice ingestion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dilute hydrochloric acid ingestion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 19
Study: 3228174

Group type: EXPERIMENTAL
Intervention: cis-retinoic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 1812095

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1000195

Group type: EXPERIMENTAL
Intervention: Intravenous dextran 70 and pneumatic leggings
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 31085097

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 60
Study: 29276914

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with pulmonary artery ablation (ablation group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mitral valve surgery (comparison group)
Number of subjects: 30
Study: 26927446

Group type: EXPERIMENTAL
Intervention: CAP/BEV/VIN (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w + vinorelbine at 25 mg/m² on days 1 + 8, q3w)
Number of subjects: 600

Group type: COMPARATOR
Intervention: CAP/BEV (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w)
Number of subjects: 600
Study: 24632102

Group type: EXPERIMENTAL
Intervention: Evaluated speaking stressor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 22396446

Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by CSF cytomorphology
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by PCR
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Meningeal dissemination (MD) detected by MRI
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: MD+ patients
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: MD- patients
Number of subjects: 415
Study: 19602719

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17251808

Group type: EXPERIMENTAL
Intervention: 1.25% castor oil emulsion
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.32% hypromellose solution
Number of subjects: 53
Study: 14734438

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (combination regimens)
Number of subjects: 0
Study: 12076220

Group type: EXPERIMENTAL
Intervention: NPPV by face mask plus standard medical therapy (n = 39)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard medical therapy alone (n = 42)
Number of subjects: 81
Study: 9872357

Group type: EXPERIMENTAL
Intervention: High CDT group (CDT >20 U/l on admission)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low CDT group (CDT <= 20 U/l on admission)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High CDT group
Number of subjects: 66
Study: 7597928

Group type: EXPERIMENTAL
Intervention: Velocity guided tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Size guided tasks
Number of subjects: 0
Study: 2193792

Group type: EXPERIMENTAL
Intervention: 1.5 million I.U. streptokinase or 1.8 million I.U. urokinase or APSAC
Number of subjects: 13
Study: 508881

Group type: EXPERIMENTAL
Intervention: Postalcoholics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irregular procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular procedure
Number of subjects: 0
Study: 31907294

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 52
Study: 31065914

Group type: EXPERIMENTAL
Intervention: Anti-hyperventilation instruction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 46
Study: 28535926

Group type: EXPERIMENTAL
Intervention: web intervention
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: web intervention and nurse facilitated workshop
Number of subjects: 322

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 322
Study: 25948266

Group type: EXPERIMENTAL
Intervention: fMRI responses for intact and phase-randomized face stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI responses in the right face-selective fusiform face area (FFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity within the visual cortical network (bilateral FFA and bilateral LOC)
Number of subjects: 0
Study: 24129613

Group type: EXPERIMENTAL
Intervention: GnRH antagonist co-treatment started on CD 2
Number of subjects: 617

Group type: COMPARATOR
Intervention: GnRH antagonist co-treatment started on CD 6
Number of subjects: 617
Study: 21327806

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.5 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: i.v. saline 5 ml (control saline group)
Number of subjects: 50
Study: 19145653

Group type: EXPERIMENTAL
Intervention: 2,500 U of botulinum toxin type B (BTxb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17530689

Group type: EXPERIMENTAL
Intervention: Videotaped OSCE assessment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Live OSCE assessment
Number of subjects: 95
Study: 15143763

Group type: EXPERIMENTAL
Intervention: Hearing aids provided to elderly individuals (15.3% of those needing them)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Audiometric diagnosis
Number of subjects: 331

Group type: COMPARATOR
Intervention: Hearing loss assessment
Number of subjects: 331
Study: 12506278

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa (1.86 mg/kg/day, 4:1 ratio) with occlusion therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with occlusion therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa and placebo groups
Number of subjects: 40
Study: 9579000

Group type: EXPERIMENTAL
Intervention: Early intervention programs (Abecedarian and CARE)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Early intervention programs (IHDP)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Early intervention programs
Number of subjects: 985
Study: 7897117

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA) (100 mg over 3 h)
Number of subjects: 5711

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5711

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 5711
Study: 2766722

Group type: EXPERIMENTAL
Intervention: Norethindrone-1mg/mestranol-50 micrograms formulations (1 + 50)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (1 + 35)
Number of subjects: 51
Study: 783197

Group type: EXPERIMENTAL
Intervention: ouabain (0.015 mg/kg body weight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no ouabain administration)
Number of subjects: 11
Study: 31057311

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 140
Study: 29798076

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline lavage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline lavage
Number of subjects: 20
Study: 26729617

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 201
Study: 25199825

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 34
Study: 21775883

Group type: EXPERIMENTAL
Intervention: Defocused ESWT (100 impulses/cm at 0.1 mJ/mm) applied once after debridement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (burn wound debridement/topical antiseptic therapy) without ESWT
Number of subjects: 50
Study: 20329656

Group type: EXPERIMENTAL
Intervention: Formoterol HFA formulation at 12 microg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Formoterol HFA formulation at 24 microg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference formoterol HFA preparation
Number of subjects: 14
Study: 17426090

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (1 mg/kg.d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (2 mg/kg.d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (1 mg/kg.d) and (2 mg/kg.d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 (highest dose groups)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15802369

Group type: EXPERIMENTAL
Intervention: Active group (estimated energy expenditure 42.4 +/- 3.7 kcal.kg(‐1).day(‐1), n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary group (32.3 +/- 0.6 kcal.kg(‐1).day(‐1), n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups after single, 1-s-duration maximum voluntary ankle dorsiflexion contractions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active group after 2 min of dynamic, repetitive ankle dorsiflexion exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary group after 2 min of dynamic, repetitive ankle dorsiflexion exercise
Number of subjects: 16
Study: 11802044

Group type: EXPERIMENTAL
Intervention: 10‐mg single dose of intramuscular injection of dexamethasone (n = 39)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 10‐mg single dose of oral dexamethasone (n = 42)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both forms)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone (with identified bacterial pathogen, n = 47)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone (without identified bacterial pathogen)
Number of subjects: 118
Study: 9660161

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study: 7667171

Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl 4 mg 4 times/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl 8 mg 4 times/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2719760

Group type: EXPERIMENTAL
Intervention: Magnesium oxide, 400 mg capsules, twice a day for 60 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 57334

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 31
Study: 31493279

Group type: EXPERIMENTAL
Intervention: Nordic Orofacial Test-Screening (NOT-S) in children with cerebral palsy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 84
Study: 31119404

Group type: EXPERIMENTAL
Intervention: Anti-hyperventilation instruction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group without instruction
Number of subjects: 46
Study: 28851310

Group type: EXPERIMENTAL
Intervention: Warfarin (post-diagnostic use)
Number of subjects: 6537

Group type: COMPARATOR
Intervention: Other types of anticoagulants
Number of subjects: 6537

Group type: COMPARATOR
Intervention: Anticoagulant non-users
Number of subjects: 6537

Group type: EXPERIMENTAL
Intervention: Warfarin (pre-diagnostic use)
Number of subjects: 6537
Study: 26316273

Group type: EXPERIMENTAL
Intervention: 2 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8 g instant decaffeinated coffee with 100 mg caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (400 ml water with 50 g glucose)
Number of subjects: 10
Study: 23942682

Group type: COMPARATOR
Intervention: Placebo (n = 74)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 200 mg of zonisamide (n = 76)
Number of subjects: 225
Study: 21533629

Group type: COMPARATOR
Intervention: Diet plus placebo (group 1, n=16)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Diet plus losartan (group 2, n=16)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Diet plus enalapril (group 3, n=14)
Number of subjects: 137
Study: 18298328

Group type: EXPERIMENTAL
Intervention: IP plus GP in SB
Number of subjects: 120

Group type: COMPARATOR
Intervention: Common gamma probe (GP) in SA
Number of subjects: 120
Study: 16737682

Group type: EXPERIMENTAL
Intervention: US-inflation manipulation (information manipulation and enhanced US)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no US-inflation manipulation)
Number of subjects: 0
Study: 14724725

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT)
Number of subjects: 35
Study: 11054200

Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine and 50 mg of ranitidine (active group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 50 mg of diphenhydramine and saline solution (control group)
Number of subjects: 91
Study: 8764816

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 600 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7962330

Group type: EXPERIMENTAL
Intervention: Granulosa cells from anovPCO
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Granulosa cells from ovPCO
Number of subjects: 64

Group type: COMPARATOR
Intervention: Granulosa cells from normal ovaries
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Follicular fluid from ovPCO
Number of subjects: 64

Group type: COMPARATOR
Intervention: Follicular fluid from normal ovaries
Number of subjects: 64